Key result
Implantable cardioverter-defibrillator (ICD) placement remains the major therapy for patients with dilated cardiomyopathy at risk of sudden cardiac death, often serving as a bridge to transplantation.
This review highlights the heterogeneity of dilated cardiomyopathy and the ongoing role of ICD placement as the major therapy for preventing sudden cardiac death in at-risk patients.
Affirms ICD as primary SCD prevention in dilated cardiomyopathy; leaves open refined risk stratification amid disease heterogeneity.
Dilated cardiomyopathy (DCM) is the most prevalent form of cardiomyopathy, and sudden cardiac death (SCD) remains a common event in young patients. The disorder is highly heterogeneous and pediatric DCM often differs from adult DCM in etiologies, risk factors, and prognosis. Prognosis may be improving, likely secondary to specialized management. Both traditional and novel markers of risk have been studied in adults and are beginning to be applied to children with DCM. The major therapy for patients considered at risk remains implantable cardioverter-defibrillator (ICD) placement, although frequently this functions as a bridge to eventual transplantation.
No takes yet. Share an insight, caveat, or question.
Hamilton et al. (2009) conducted a review in Dilated cardiomyopathy (DCM) and sudden cardiac death (SCD). Implantable cardioverter-defibrillator (ICD) was evaluated. Implantable cardioverter-defibrillator (ICD) placement remains the major therapy for patients with dilated cardiomyopathy at risk of sudden cardiac death, often serving as a bridge to transplantation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: